Novo Nordisk says it’s suing Hims to halt obesity drug copycats
The makers of blockbuster GLP-1 drugs, Novo and Indianapolis-based Eli Lilly and Co., have long complained the U.S. Food and Drug Administration hasn’t done enough to stop the proliferation of cheap, compounded weight-loss drugs.